Abstract: An object of the present invention is to achieve drug repositioning and/or drug repurposing without conducting animal experiments. The problems are solved by a method for predicting a new indication for a known drug of interest or its equivalent substance, including the step of predicting a new indication for the known drug of interest or its equivalent substance using an artificial intelligence model trained based on test data which is information about adverse events and/or side effects reported for the known drug of interest or its equivalent substance.

Abstract: The present disclosure provides a method for predicting an indication for a test substance in humans, a prediction device for predicting an indication for a test substance in humans, a computer program for predicting an indication for a test substance in humans, and a prediction system for predicting an indication for a test substance in humans.

Abstract: Actions, such as effects and adverse-events, of a test substance in humans are predicted by using an artificial intelligence model trained by a method for training an artificial intelligence model, the method including inputting into the artificial intelligence model a set of first training data and second training data or a set of the second training data to train the artificial intelligence model.

Abstract: Disclosed in the description is a method for correcting a count data set for single-cell RNA-Seq analysis, including weighting a count data set for single-cell RNA-Seq analysis obtained from cells to be analyzed or predicted for the cells to be analyzed based on the total RNA content of each cell type corresponding to the cells to be analyzed.

Abstract: An object of the present invention is to achieve prediction of an indication, drug repositioning and/or drug repurposing for a drug with no known adverse events and/or side effects based on adverse events and/or side effects. The problem is solved by a method for predicting an indication for a drug of interest or its equivalent substance, including inputting estimated adverse event-related information and/or estimated side effect-related information estimated from a set of data indicating the behavior of a biomarker in one or more organs collected from non-human animals to which the drug of interest or its equivalent substance has been administered as a test substance into an artificial intelligence model for prediction as test data to predict an indication for the drug of interest or its equivalent substance.

Abstract: An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease. A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein.

Abstract: An apparatus 1 comprises a subject data obtaining unit 11 for obtaining subject data M4 of an inter-organ cross talk indicator in each organ other than a specific organ, a pattern similarity calculation unit 12 for calculating, by comparing the subject data M4 with standard data 1 of the inter-organ cross talk indicator, similarity of patterns of the inter-organ cross talk indicators, and a prediction unit 13 for predicting the presence of a specific disease and/or the stage of the specific disease by using the similarity as a measure.

Abstract: An apparatus 1 comprises a subject data obtaining unit 11 for obtaining subject data M4 of an inter-organ cross talk indicator in each organ other than a specific organ, a pattern similarity calculation unit 12 for calculating, by comparing the subject data M4 with standard data 1 of the inter-organ cross talk indicator, similarity of patterns of the inter-organ cross talk indicators, and a prediction unit 13 for predicting the presence of a specific disease and/or the stage of the specific disease by using the similarity as a measure.

Abstract: An apparatus 1 comprises a subject data obtaining unit 11 for obtaining subject data M4 of an inter-organ cross talk indicator in each organ other than a specific organ, a pattern similarity calculation unit 12 for calculating, by comparing the subject data M4 with standard data 1 of the inter-organ cross talk indicator, similarity of patterns of the inter-organ cross talk indicators, and a prediction unit 13 for predicting the presence of a specific disease and/or the stage of the specific disease by using the similarity as a measure.

Abstract: An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease. A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein.

Abstract: Actions, such as effects and adverse-events, of a test substance in humans are predicted by using an artificial intelligence model trained by a method for training an artificial intelligence model, the method including inputting into the artificial intelligence model a set of first training data and second training data or a set of the second training data to train the artificial intelligence model.

Abstract: An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein.

Abstract: An apparatus 1 comprises a subject data obtaining unit 11 for obtaining subject data M4 of an inter-organ cross talk indicator in each organ other than a specific organ, a pattern similarity calculation unit 12 for calculating, by comparing the subject data M4 with standard data 1 of the inter-organ cross talk indicator, similarity of patterns of the inter-organ cross talk indicators, and a prediction unit 13 for predicting the presence of a specific disease and/or the stage of the specific disease by using the similarity as a measure.

Abstract: This invention provides a device for screening a candidate substance for an active ingredient to prevent or treat declined kidney function etc. A screening device 1 for screening a candidate substance for an active ingredient to prevent or treat declined kidney function etc. comprises a first measurement value obtaining unit 11 for obtaining a measurement value of a kidney function prediction marker protein and/or a measurement value of mRNA of the protein in a test-substance-treated specimen, and a candidate substance determination unit 14 for determining that the test substance is a candidate substance for the active ingredient based on the measurement value(s) obtained by the first measurement value obtaining unit 11.

Abstract: A device 1 comprises a measurement value obtaining unit 13 for obtaining a measurement value M2 relating to at least one protein selected from the group consisting of kidney function prediction markers contained in a specimen collected from a subject and/or a measurement value M3 of at least one mRNA selected from the group consisting of kidney function prediction markers contained in a specimen collected from the subject, and a kidney function evaluation unit 14 for evaluating kidney function based on the measurement value(s) obtained by the obtaining unit.